Pathologie osseuse et insuffisance rénale. Actualités sur les explorations biologiques

Fournier, 1971, Etiologyof hyperparathyroidism and bone disease during chronic hemodialysis, I. Association of bone disease with potentially etiologic factors; II. Factors affecting serum immunoreactive parathyroid hormone, J Clin Invest, 50, 592, 10.1172/JCI106529 Kronenberg, 1994, Parathyroid hormone biosynthesis and metabolism, 125 Fournier, 1997, Ostéopathie adynamique : quelle signification clinique, 96 Bouillon, 1990, Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies, Clin Chem, 36, 271, 10.1093/clinchem/36.2.271 Cohen Solal, 1991, Comparison of intact, midregion and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients, J Clin Endocrinol Metab, 73, 516, 10.1210/jcem-73-3-516 Fournier, 2001, Optimal range of plasma concentration of true 1-84 parathyroid hormone in patients on maintenance dialysis, J Clin Endocrinol Metab, 86, 1840, 10.1210/jc.86.4.1840 Fournier, 2001, Adynamic bone disease in uremia, 268 Brossard, 1996, Accumulation of a non (1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values, J Clin Endocrinol Metab, 81, 3923, 10.1210/jc.81.11.3923 Lepage, 1998, A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples, Clin Chem, 44, 805, 10.1093/clinchem/44.4.805 John, 1999, A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure, J Clin Endocrinol Metab, 84, 4287, 10.1210/jc.84.11.4287 Massry, 1973, Skeletal resistance to parathyroid hormone in renal failure, Studies in 105 human subjects, Ann Intern M, 78, 357, 10.7326/0003-4819-78-3-357 Monier-Faugere, 2001, Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients, Kidney Int, 60, 1460, 10.1046/j.1523-1755.2001.00949.x Quarles, 1992, Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia, J Clin Endocrinol Metab, 75, 145, 10.1210/jc.75.1.145 Wang, 1995, Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity, Am J Kidney Dis, 26, 836, 10.1016/0272-6386(95)90453-0 Slatopolsky, 2000, A novel mechanism for skeletal resistance in uremia, Kidney Int, 58, 753, 10.1016/S0085-2538(15)47156-X Hamdy, 1995, Effect of alfacalcidol on natural course of bone disease in mild to moderate renal failure, Br Med J, 310, 358, 10.1136/bmj.310.6976.358 Torres, 1995, Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH, Kidney Int, 47, 1434, 10.1038/ki.1995.201 Fournier, 1995, Optimal plasma concentrations of intact parathyroid hormone in predialysis patients, Nephrol Dial Transplant, 10, 2376, 10.1093/ndt/10.12.2376 Fournier, 1997, Invasive versus non-invasive diagnosis of renal bone disease, Curr Opin Nephrol Hypertens, 6, 333, 10.1097/00041552-199707000-00006 Machu Restaux, 1996, Évaluation de la phosphatase alcaline osseuse sérique au cours des affections métaboliques de l'os. Comparaison des méthodes immunologiques et électrophorétique, Immunoan Biol Spec, 11, 259 Couttenye, 1996, Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients, Nephrol Dial Transplant, 11, 1065, 10.1093/oxfordjournals.ndt.a027457 Coen, 1996, Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure, Nephrol Dial Transplant, 11, 813, 10.1093/oxfordjournals.ndt.a027404 Urena, 1996, Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients, J Am Soc Nephrol, 7, 506, 10.1681/ASN.V73506 Qi, 1995, Predictive value of serum parathyroid hormone levels for bone turn-over in patients on chronic maintenance dialysis, Am J Kidney Dis, 26, 622, 10.1016/0272-6386(95)90599-5 Gerakis, 1996, Serum procollagen type I carboxyterminal propeptide in CAPD and hemodialysis patients, Perit Dial Int, 16, S309, 10.1177/089686089601601S58 Gerakis, 1996, Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis, Nephrol Dial Transplant, 11, 2430, 10.1093/oxfordjournals.ndt.a027210 Lafage-Proust, 2000, Heterogenity of bone histology in hypercalcemic renal transplant recipients: diagnostic value of biochemical marker of bone remodeling, J Bone Miner Res, 15, S570